FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer
FDA DecisionapprovedRucaparibPositive
AI Analysis
Summary
The FDA approved rucaparib (Rubraca) on December 17, 2025, for adults with BRCA-mutated metastatic castration-resistant prostate cancer who have received prior androgen receptor-directed therapy. This represents a regular approval for a targeted cancer treatment addressing a specific genetic biomarker.
Outcome Details
FDA granted regular approval to rucaparib for metastatic castration-resistant prostate cancer with deleterious BRCA mutations
Importance:8/10
Sentiment:
0.90
FDA approvaloncologyprostate cancerBRCA mutationprecision medicine
Read the original article
Published by FDA Drugs (New Approvals & NDA) on May 6, 2026 11:51 AM